Original Article
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
N Engl J Med 2008; 359:2442-2455December 4, 2008
- Abstract
Background
Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase.
Methods
In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)–negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of <400 copies per milliliter), histologic improvement, serologic response, normalization of alanine aminotransferase levels, and development of resistance mutations.
Results
At week 48, in both studies, a significantly higher proportion of patients receiving tenofovir DF than of those receiving adefovir dipivoxil had reached the primary end point (P<0.001). Viral suppression occurred in more HBeAg-negative patients receiving tenofovir DF than patients receiving adefovir dipivoxil (93% vs. 63%, P<0.001) and in more HBeAg-positive patients receiving tenofovir DF than patients receiving adefovir dipivoxil (76% vs. 13%, P<0.001). Significantly more HBeAg-positive patients treated with tenofovir DF than those treated with adefovir dipivoxil had normalized alanine aminotransferase levels (68% vs. 54%, P=0.03) and loss of hepatitis B surface antigen (3% vs. 0%, P=0.02). At week 48, amino acid substitutions within HBV DNA polymerase associated with phenotypic resistance to tenofovir DF or other drugs to treat HBV infection had not developed in any of the patients. Tenofovir DF produced a similar HBV DNA response in patients who had previously received lamivudine and in those who had not. The safety profile was similar for the two treatments in both studies.
Conclusions
Among patients with chronic HBV infection, tenofovir DF at a daily dose of 300 mg had superior antiviral efficacy with a similar safety profile as compared with adefovir dipivoxil at a daily dose of 10 mg through week 48. (ClinicalTrials.gov numbers, NCT00116805 and NCT00117676.)
Media in This Article
Figure 1
Suppression of HBV DNA Levels during the 48-Week Study Period.Figure 2
Mean Plasma HBV DNA Levels.Article Activity
- Article
Chronic hepatitis B virus (HBV) infection is a major health problem.1-3 Since most patients with chronic HBV infection require long-term therapy,4-6 there is a need for new drugs with potent antiviral activity and established long-term safety, as well as a proven low rate of HBV antiviral resistance, a high genetic barrier (i.e., requiring more than one amino acid substitution to confer resistance to HBV treatment), or both.
The ultimate goal of treatment of chronic HBV infection is to prevent liver complications. This goal is seldom achieved through hepatitis B surface antigen (HBsAg) loss and seroconversion, which are associated with sustained immunologic and virologic control of the virus. In hepatitis B e antigen (HBeAg)–positive chronic HBV infection, HBeAg loss and seroconversion are associated with a reduction in HBV DNA levels but they are not curative, and the emergence of precore escape mutations may lead to active HBeAg-negative, chronic hepatitis with attendant long-term complications.7 Maintenance of viral suppression with oral therapy is often the best that can be achieved. Viral suppression maintained by treatment with lamivudine has been shown to reduce the progression of the disease to decompensation and the development of hepatocellular carcinoma in patients with cirrhosis.8
Seven drugs are licensed for the treatment of chronic HBV infection: lamivudine,9 interferon alfa,10,11 adefovir dipivoxil,12 peginterferon alfa-2a,13 entecavir,14 telbivudine,15 and tenofovir disoproxil fumarate (DF). Interferons are not recommended for use in patients with decompensation or immunosuppression; they may have treatment-limiting side effects, and they require parenteral administration. Oral nucleosides, although potent, have been limited by the development of resistance mutations in the HBV polymerase–reverse transcriptase.16,17
Tenofovir DF, the oral prodrug of tenofovir, is a nucleotide analogue that inhibits viral polymerases by direct binding, and after incorporation into DNA, by termination of the DNA chain due to the absence of a requisite 3′ hydroxyl on the tenofovir molecule.18
Tenofovir DF is currently approved in the United States and more than 50 other countries for the treatment of human immunodeficiency virus type 1 (HIV-1), and it was recently approved for the treatment of chronic HBV infection in the United States, Canada, Europe, Australia, and Turkey.
Tenofovir is a potent and selective inhibitor of HBV DNA polymerase–reverse transcriptase in vitro.19 It remains active against lamivudine-resistant HBV,20-23 and it has known activity against HBV both in patients with HBV monoinfection24-26 and in patients with HIV-1 and HBV coinfection.27-29 Two phase 3 studies were designed to compare the safety and efficacy of tenofovir DF at a dose of 300 mg with adefovir dipivoxil at a dose of 10 mg, administered once daily, in HBeAg-negative patients (Study 102) or HBeAg-positive patients (Study 103).
Methods
Study Design
With the use of a central, interactive voice-response system (ClinPhone), we randomly assigned patients in a 2:1 ratio to receive tenofovir DF or adefovir dipivoxil. The treatment assignments were stratified according to serum alanine aminotransferase level (<4 times the upper limit of the normal range or ≥4 times the upper limit of the normal range) in Study 103 and according to previous treatment with lamivudine or emtricitabine (<12 weeks or ≥12 weeks) in Study 102. In both studies, treatment assignments were also stratified according to geographic region (Europe, North America, or Australia and New Zealand). Within each stratum, treatment groups were balanced by permuted blocks of size 6. Patients were enrolled at 106 clinical sites in 15 countries across North America (31 sites), Europe (60 sites), and the Asia-Pacific region (15 sites).
Patients were recruited from May 2005 through June 2006 and were treated with medication in a double-blind study for 48 weeks. Patients underwent two liver biopsies: one pretreatment biopsy performed within 6 months before screening and the other biopsy performed between weeks 44 and 48. Patients returned to the clinic every 4 weeks for laboratory assessments of serum chemical and hematologic values, liver function, and HBV DNA levels and for documentation of any adverse events. Hepatitis B serologic markers (HBeAg and HBsAg) were assessed every 12 weeks. Covance Laboratories and affiliates conducted the laboratory tests. Patients who completed 48 weeks of treatment and underwent the second liver biopsy were given the option to begin treatment with open-label tenofovir DF for up to 7 more years. Blinding of the original treatment assignment was maintained. Patients who discontinued double-blind treatment were followed after treatment for 24 weeks or until the initiation of an alternative hepatitis B therapy.
Resistance surveillance included genotypic analysis of the HBV polymerase in all patients at baseline, in patients with viremia who had an HBV DNA level of 400 copies per milliliter (69 IU per milliliter) or more at week 48 (or at the time that treatment was discontinued, in the case of patients who did not complete 48 weeks of treatment), and in patients with virologic breakthrough (i.e., a confirmed HBV DNA level of ≥400 copies per milliliter after a documented level of less than 400 copies per milliliter or a confirmed log10 increase of 1.0 or more from the nadir level). The population-based dideoxy sequencing assay used has a viral-load requirement of 400 copies per milliliter or more. Resistance surveillance testing was conducted by Gilead Sciences.
During double-blind treatment, an external independent data monitoring committee reviewed the safety results five times. The study was conducted in accordance with international scientific and ethical standards, including but not limited to the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. The study was approved by independent ethics committees or institutional review boards at the study sites. Written informed consent was obtained from all patients before any procedures were performed.
The studies were designed by Gilead Sciences in collaboration with their scientific advisors, and the primary end point was negotiated with the Food and Drug Administration. Clinical data were collected and monitored by ICON Clinical Research (in North America, Western Europe, and the Asia-Pacific region) and Quintiles (in Eastern Europe). Data from case-report forms were entered into the database by ICON Clinical Research (Dublin), and the data were unblinded for statistical analysis after the database was locked. Gilead Sciences performed all statistical analyses and wrote the manuscript in collaboration with the lead academic authors. The academic authors vouch for the veracity and completeness of the reported data and data analyses.
Study Population
The studies enrolled patients 18 to 69 years of age who had HBeAg-negative or HBeAg-positive chronic hepatitis B with compensated liver disease and pretreatment liver-biopsy specimens that showed a Knodell necroinflammatory score of 3 or more (on a scale of 0 to 18, with higher scores indicating more severe chronic hepatitis). All patients had been HBsAg-positive for at least 6 months before screening. In Study 102, patients had alanine aminotransferase levels that were more than 1 time and less than 10 times the upper limit of the normal range and HBV DNA levels that were higher than 105 copies per milliliter. Patients either had received less than 12 weeks of treatment with any nucleoside or nucleotide or had received lamivudine or emtricitabine for at least 12 weeks (the lamivudine-treatment subgroup). In Study 103, patients had alanine aminotransferase levels that were more than 2 times and less than 10 times the upper limit of the normal range and HBV DNA levels of more than 106 copies per milliliter; these patients had received less than 12 weeks of treatment with any nucleoside or nucleotide. Key exclusion criteria were coinfection with HIV-1 or hepatitis C or D virus, evidence of hepatocellular carcinoma, a creatinine clearance of less than 70 ml per minute, a hemoglobin level of less than 8 g per deciliter, a neutrophil count of less than 1000 per cubic millimeter, and liver decompensation or failure.
End Points
The primary efficacy end point at week 48 was defined as the combination of an HBV DNA level of less than 400 copies per milliliter and histologic improvement (i.e., a reduction of 2 or more points in the Knodell necroinflammatory score without an increase in fibrosis). HBV DNA was measured with the use of the Roche Cobas TaqMan polymerase-chain-reaction assay, which has a lower limit of quantitation of 169 copies per milliliter (29 IU per milliliter). Since the viral-load requirement for the population-based dideoxy sequencing assay used for resistance surveillance was 400 copies per milliliter, this was the threshold level for the primary end point. Paired liver-biopsy slides (i.e., a specimen from the first biopsy, performed before treatment, and a specimen from the second biopsy, performed during treatment) were evaluated by one independent central pathologist, who remained unaware of both the assigned treatment and the biopsy sequence; biopsy slides were scored according to the Knodell schema.30
Secondary end points included HBV DNA and alanine aminotransferase levels over time and the proportion of patients with HBV DNA levels of less than 400 copies per milliliter, normalized alanine aminotransferase levels, histologic improvement, HBeAg and HBsAg loss and seroconversion, and resistance mutations in HBV polymerase.
Safety Analysis
The safety analyses included all patients who received at least one dose of a study drug and all events that occurred during double-blind treatment. Adverse events, serious adverse events, laboratory abnormalities, discontinuation of the study drug due to adverse events, and deaths were evaluated. In this protocol, alanine aminotransferase flares, were considered to be serious adverse events. Flares were defined as an alanine aminotransferase level that was more than twice the baseline level and more than 10 times the upper limit of the normal range, with or without associated symptoms, or a confirmed elevation in the alanine aminotransferase level with confirmed changes outside the normal range in other laboratory values that were suggestive of worsening hepatic function (i.e., a total bilirubin level ≥2 mg per deciliter [34 μmol per liter] above the baseline value, a prothrombin time ≥2 seconds higher than the baseline value or an international normalized ratio ≥0.5 over baseline, or a serum albumin level ≥1 g per deciliter below the baseline value).
Resistance Surveillance and Baseline Genotyping
Phylogenetic mapping of individual HBsAg nucleotide sequences was used to determine the viral genotype (A through H) at baseline. At week 48, changes in the HBV polymerase–reverse-transcriptase region from baseline were identified in patients with either persistent viremia or virologic breakthrough. Changes in the amino acid sequence of the HBV polymerase–reverse-transcriptase domain were further evaluated to determine whether these substitutions occurred at polymorphic or conserved sites. All conserved site substitutions were phenotypically assessed with in vitro cell-culture assays to measure susceptibility to tenofovir. Polymorphic changes were also phenotyped if they occurred in more than one patient.
Statistical Analysis
The primary end point was a composite of HBV DNA suppression and histologic improvement. The population for analysis included all patients who were randomly assigned to treatment and who received at least one dose of study medication; no patient was excluded from the analysis because of a protocol deviation. In Study 102, we calculated that the planned sample size of 300 patients (200 in the tenofovir DF group and 100 in the adefovir dipivoxil group) would provide at least 85% power to detect an absolute difference of 19% in the proportion of patients with a complete response at week 48, on the basis of a two-sided significance level of 0.05 and assuming a complete response rate of 28% in the adefovir dipivoxil group. In Study 103, we calculated that the planned sample size of 240 patients (160 in the tenofovir DF group and 80 in the adefovir dipivoxil group) would provide at least 85% power to detect an absolute difference of 13% in the proportion of patients with a complete response at week 48, on the basis of a two-sided significance level of 0.05 and assuming an 18% response rate in the adefovir dipivoxil group.
The difference between treatment groups was evaluated with the use of a two-sided 95% confidence interval stratified according to the baseline level of alanine aminotransferase (in Study 102, a value that was less than or equal to twice the upper limit of the normal range vs. a value that was more than twice the upper limit; in Study 103, a value that was less than or equal to four times the upper limit of the normal range vs. a value that was more than four times the upper limit). For the intention-to-treat analysis, patients who did not have paired liver-biopsy specimens that could be evaluated or who did not undergo HBV DNA assessment were considered not to have had treatment responses.
Finally, observed data (on-treatment analysis) for the HBV DNA and alanine aminotransferase levels over time as well as the proportion of patients with an HBV DNA level of less than 400 copies per milliliter were analyzed.
To assess whether the treatment effect was consistent among the different patient subpopulations, we evaluated the primary end point and its components in 10 integrated subgroup analyses based on prespecified definitions and performed with data pooled from Study 102 and Study 103. Subgroups were defined according to age, sex, race or ethnic group, baseline HBV DNA level, baseline alanine aminotransferase level in relation to the upper limit of the normal range, normal baseline alanine aminotransferase level versus abnormal level, Knodell necroinflammatory score at screening, Knodell fibrosis score at screening, baseline genotype, and receipt or nonreceipt of previous treatment with lamivudine or emtricitabine. In addition to the response within each subgroup, the heterogeneity of the response across subgroups was evaluated with the use of a logistic-regression model for each subgroup studied. Independent terms in the model included treatment, subgroup, and interaction between treatment and subgroup. If the interaction was not significant at the 0.01 level (after adjustment for multiple comparisons), then it was concluded that there was homogeneity of response across the categories of the subgroup. In addition, forest plots were constructed to compare treatment effects across the subgroups.
Demographic and baseline characteristics were compared with the use of a two-sided Mantel–Haenszel test for categorical data and a Wilcoxon rank-sum test for continuous data, with a significance level of 0.05. All reported P values are two-sided and have not been adjusted for multiple testing. No interim analyses were performed other than summary tabulations of safety data for review by the independent data monitoring committee.
Results
Study Population
In Study 102, among the 846 patients with HBeAg-negative infection who were screened, 382 patients underwent randomization and 375 patients received at least one dose of the assigned study drug (250 patients received tenofovir DF and 125 patients received adefovir dipivoxil). Most patients who did not meet the eligibility criteria had a low alanine aminotransferase level (31%), a low HBV DNA level (40%), or both, or they had exclusionary serologic findings — that is, coinfection, a positive test for HBeAg, or a negative test for antibodies against HBeAg (anti-HBe antibodies) (14%). Six patients receiving tenofovir DF (2%) and four receiving adefovir dipivoxil (3%) withdrew from the study before week 48. Five patients discontinued tenofovir DF because of adverse events, and one patient was lost to follow-up; no patients discontinued tenofovir DF before week 48 because of lack of efficacy.
In Study 103, among the 603 patients with HBeAg-positive infection who were screened, 272 patients underwent randomization and 266 patients received at least one dose of the assigned study drug (176 patients received tenofovir DF and 90 received adefovir dipivoxil). Most patients who did not meet eligibility criteria had a low alanine aminotransferase level (54%), a low HBV DNA level (12%), or both or they had exclusionary serologic findings (20%). Ten patients who received tenofovir DF (6%) and five patients who received adefovir dipivoxil (6%) discontinued treatment before week 48; most withdrew consent or were lost to follow-up. No patients discontinued tenofovir DF because of adverse events or lack of efficacy. Diagrams showing screening, enrollment, and treatment of patients in both studies are included in the Supplementary Appendix, available with the full text of this article at www.nejm.org.
In both studies, the two treatment groups were well balanced with respect to baseline demographic and clinical characteristics (Table 1Table 1
Demographic and Baseline Characteristics of the Study Patients.). Overall, 20% of the patients had cirrhosis at baseline. Patients enrolled in Study 102 were generally older than those in Study 103 (mean age, 44 years vs. 34 years). HBV DNA levels were about 2 log10 copies per milliliter lower in the patients in Study 102, who were HBeAg-negative, than in the patients in Study 103, who were HBeAg-positive; 18% of the HBeAg-negative patients had previously received lamivudine. A total of 347 of 375 patients in Study 102 (93%) and 236 of 266 patients (89%) in Study 103 completed 48 weeks of treatment and had paired biopsy specimens that could be evaluated and HBV DNA results.Histologic and Virologic Response
In both studies, a significantly greater proportion of patients who received tenofovir DF than patients who received adefovir dipivoxil reached the primary end point of both an HBV DNA level of less than 400 copies per milliliter and histologic improvement (71% vs. 49% among HBeAg-negative patients and 67% vs. 12% among HBeAg-positive patients (Table 2Table 2
Efficacy Results at 48 Weeks.). Histologic improvement was similar between treatment groups; most patients had reduced necroinflammation, and few patients had worsening fibrosis.Among the HBeAg-negative patients, 93% of all the patients who received tenofovir DF had a plasma HBV DNA level of less than 400 copies per milliliter by week 48 (intention-to-treat analysis), and 97% of whose who were receiving tenofovir DF at week 48 had an HBV DNA level of less than 400 copies per milliliter (observed data) (Table 2). At week 24, a total of 85% of the patients who received tenofovir DF had HBV DNA suppression below this level (Figure 1AFigure 1
Suppression of HBV DNA Levels during the 48-Week Study Period.). The change in the level of HBV DNA was characterized by a precipitous decrease by week 4. At week 12, the mean HBV DNA level was 3 log10 copies per milliliter as compared with a baseline HBV DNA level of approximately 7 log10 copies per milliliter (Figure 2AFigure 2Mean Plasma HBV DNA Levels.). Patients with lower baseline HBV DNA levels had undetectable levels of HBV DNA sooner than did patients with higher baseline levels (Figure 3A and 3BFigure 3
Reduction in HBV DNA from Baseline through Week 12 in Patients Receiving Tenofovir DF.).Among HBeAg-positive patients, 76% of patients who received tenofovir DF had an HBV DNA level of less than 400 copies per milliliter at week 48, and 49% of patients who received tenofovir DF had an HBV DNA level of less than 400 copies per milliliter at week 24. With the use of observed data, 83% of the patients receiving tenofovir DF treatment at week 48 had an HBV DNA level of less than 400 copies per milliliter (Figure 1B and Table 2). HBV DNA suppression was characterized by a rapid 4.5-log reduction in the HBV DNA level by week 12, with complete viral suppression in increasing numbers of patients over time (Figure 2B).
An evaluation of the treatment response in subgroups defined by baseline characteristics showed no significant interactions at the 0.01 alpha level. Among patients treated with tenofovir DF, 90% of patients who had received lamivudine versus 88% of those who had not received lamivudine had HBV DNA suppression to less than 400 copies per milliliter (see the forest plots in the Supplementary Appendix).
Biochemical and Serologic Response
At baseline, 94% of patients in Study 102 and 97% of patients in Study 103 had elevated alanine aminotransferase levels (>34 IU per milliliter in women and >43 IU per milliliter in men). In Study 102 (HBeAg-negative patients), similar proportions of patients in the two treatment groups had normalized alanine aminotransferase levels at week 48, whereas in Study 103 (HBeAg-positive patients), a significantly greater proportion of patients in the tenofovir DF group had normalized alanine aminotransferase levels (68% vs. 54%, P=0.03). Overall, at week 48, patients who received tenofovir DF had a mean alanine aminotransferase level of approximately 35 IU per milliliter (Table 2). In Study 103, similar proportions of patients in the tenofovir DF group and the adefovir dipivoxil group had HBeAg seroconversion (21% and 18%, respectively, P=0.36), and significantly more patients in the tenofovir DF group had HBsAg loss (3% vs. 0%, P=0.02) (Table 2). Two patients with HBsAg loss also had seroconversion to antibodies against hepatitis B surface antigen (anti-HBs antibodies). All five patients who lost HBsAg were white (three men and two women), and they ranged in age from 24 to 44 years; two patients were infected with HBV genotype A, and three patients infected with HBV genotype D. Four of the five patients had bridging fibrosis or cirrhosis at study entry. None of the patients who were HBeAg-seronegative at baseline (i.e., all the patients in Study 102) had HBsAg loss or seroconversion.
Resistance Surveillance
No genotypic substitutions in polymerase–reverse transcriptase associated with decreased sensitivity to tenofovir were detected among patients who received tenofovir DF and were evaluated at week 48 in either Study 102 or 103. Among the 426 patients receiving tenofovir DF, 39 patients (8 patients in Study 102 and 31 patients in Study 103) had viremia (an HBV DNA level ≥400 copies per milliliter); 10 had virologic breakthrough and 29 did not. Fifteen patients had polymorphic site changes, 2 had conserved site changes, 11 had no change, and 10 could not be genotyped. One additional patient, who discontinued treatment early, had virus with polymorphic site changes. The two conserved site changes occurred without virologic breakthrough; phenotypic evaluation showed either full susceptibility to tenofovir DF or a nonviable, nonreplicative virus in cell culture. Of the 10 patients with virologic breakthrough, 7 had no changes, and 3 had polymorphic changes but not the same changes. Successful phenotyping in 6 of these 10 patients showed full phenotypic susceptibility to tenofovir in vitro. Phenotypic analysis for the remaining four patients could not to be performed because of a low viral load that did not allow for amplification and cloning of the full-length HBV genome. A documented history of nonadherence to treatment, serum tenofovir DF levels below the level of quantitation (10 ng per milliliter), or both — findings that suggested nonadherence — may have contributed to virologic breakthrough in at least two thirds of these patients.
Among the 215 patients who were randomly assigned to receive adefovir dipivoxil, the rtN236T mutation developed in 1 patient, and the rtA181T mutation developed in 3 patients. Clonal analysis of the patients' baseline HBV revealed the presence of quasi-species with the rtA181T mutation (0.2 to 11.3%) and the rtM204I mutation (1.2 to 16.1%), indicating previous exposure to lamivudine or infection with a lamivudine-resistant virus. These results are consistent with previous studies that showed a higher rate of adefovir-dipivoxil resistance in patients with lamivudine-resistant virus.31,32
Safety
The safety profiles observed in both studies were consistent with the known safety profiles for tenofovir DF in patients with HIV infection and for the safety profiles for adefovir dipivoxil in patients with HBV infection.33,34 Nausea was the only adverse event that consistently occurred more frequently in the group of patients who received tenofovir DF than in the group of patients who received adefovir dipivoxil. Among the cases of nausea that were considered to be related to tenofovir DF, nausea was mild except for one case of grade 2 (moderate) nausea (Table 3Table 3
Clinical Adverse Events and Laboratory Abnormalities.).In both studies, similar proportions of patients in the two treatment groups had a serious adverse event, and few events were considered to be related to the study drug (Table 3). Overall, the only serious clinical adverse event reported in more than one patient was hepatocellular carcinoma (in three patients in Study 102), which is a known complication of chronic HBV infection. No deaths were reported during either study. The following five adverse events led to discontinuation of tenofovir DF in Study 102 and occurred in one patient each: anorexia, bladder neoplasm, fatigue, cervical carcinoma, and feeling hot. No patient in Study 103 discontinued tenofovir DF because of an adverse event.
The frequency of alanine aminotransferase flares during treatment was similar in the two groups (Table 3). Nearly all alanine aminotransferase flares occurred within the first 8 weeks after the start of treatment with tenofovir DF, were limited to increases in aminotransferase levels that were greater than 10 times the upper limit of the normal range and twice the baseline level, with continued and profound decreases in the HBV DNA level, and resolved within 4 to 8 weeks without interruption or discontinuation of treatment. Grade 4 alanine aminotransferase flares were associated with HBeAg loss or seroconversion in 63% of patients, one of whom eventually had seroconversion to anti-HBs antibodies.
There was no evidence of compromised renal function or renal tubular dysfunction in any patient who received tenofovir DF (Table 3). None of the patients who received tenofovir DF had a confirmed increase from baseline in the serum creatinine level of 0.5 mg per deciliter (44.2 μmol per liter) or more or a confirmed calculated creatinine clearance of less than 50 milliliters per minute (Table 3). In Study 103, there was a confirmed increase in the serum creatinine level of 0.5 mg per deciliter above baseline in one patient who received adefovir dipivoxil.
Discussion
In patients with compensated chronic HBV infection, tenofovir DF was superior to adefovir dipivoxil with respect to the primary end point of antiviral efficacy. Viral suppression occurred in approximately 80% of HBeAg-positive patients and 95% of HBeAg-negative patients who received tenofovir DF, and almost three fourths of the patients had histologic improvement. In both studies, histologic improvement was similar in the two treatment groups at 48 weeks. Multiple reports have shown that maintenance of viral suppression is a key determinant of therapeutic outcomes for patients with chronic HBV infection8,35-37; these reports include a review of 26 prospective clinical trials showing that a sustained HBV DNA response was correlated with serologic, histologic, or biochemical responses.38
HBsAg loss or seroconversion heralds durable immune control of the virus. In the phase 3 study involving HBeAg-positive patients, the proportion of patients with loss of HBsAg during the 48-week treatment period was significantly higher in the tenofovir DF group than in the adefovir dipivoxil group. In the absence of HBsAg loss, long-term treatment with oral therapies is often required to maintain viral suppression. Consequently, well-tolerated, potent therapies that offer a strong genetic barrier against the development of resistance are desirable, since antiviral resistance and poor adherence are key risk factors for treatment failure and subsequent reversal of clinical improvement.39-43 The high proportion of patients who received tenofovir DF and had viral suppression portends a potential long-term advantage in preventing the emergence of resistance and attendant loss of response. No genotypic substitutions in polymerase–reverse transcriptase associated with either decreased sensitivity to tenofovir or known resistance to other anti-HBV therapies were detected in either the HBeAg-negative patients or the HBeAg-positive patients after 48 weeks of treatment, but resistance patterns with long-term treatment are not known. In an effort to define the resistance profile for tenofovir DF, resistance surveillance will continue for at least 7 more years.
No safety signals were observed for tenofovir DF in patients with chronic HBV infection. Although renal events have been observed with the use of tenofovir DF in patients with HIV infection, predominantly in patients with preexisting renal disease, no renal toxic effects were observed during 48 weeks of treatment with tenofovir DF in patients with chronic HBV infection who had preserved renal function at baseline. In these studies of tenofovir DF for chronic HBV infection, there were insufficient data to characterize exacerbation after treatment. However, there is a known risk after discontinuation of any oral anti-HBV treatment, and monitoring of liver-function tests for several months is required. Alanine aminotransferase flares during treatment with tenofovir DF were infrequent, transient, and associated with continuous and profound decreases in the HBV DNA level. Seroconversion to anti-HBe antibodies in a majority of these patients suggested enhanced immunologic activity against HBV that coincided with a treatment-induced reduction in the viral load. Treatment with nucleoside analogues also can result in lactic acidosis and hepatomegaly with steatosis, but no patients in these studies had these adverse events.
In these 48-week phase 3 studies, tenofovir DF was shown to be a potent therapy for the treatment of HBeAg-negative and HBeAg-positive chronic HBV infection. Tenofovir DF was just as effective in suppressing HBV DNA levels in patients who had not received treatment as in patients who had previously received lamivudine. In light of its favorable long-term safety record in patients with HIV-1 infection, tenofovir DF should be considered for the treatment of chronic HBV infection.
Presented in part at the 58th annual meeting of the American Association for the Study of Liver Diseases, Boston, November 2, 2007.
Supported by Gilead Sciences.
Dr. Marcellin reports receiving grant support and lecture and consulting fees from Hoffmann–La Roche, Schering-Plough, Gilead Sciences, Bristol-Myers Squibb, and Idenix-Novartis and grant support and consulting fees from Vertex, Human Genome Sciences, Cytheris, InterMune, Wyeth, Pharmasset, and Tibotec; Dr. Heathcote, receiving consulting fees and grant support from Ortho Biotech, Indenix Pharmaceuticals, Human Genome Sciences, Gilead Sciences, GlaxoSmithKline, Debio, Schering-Plough, Vertex, and Hoffmann–La Roche; Dr. Buti, receiving lecture and consulting fees from Gilead Sciences and Novartis and lecture fees from Bristol-Myers Squibb; Dr. Gane, receiving consulting fees from GlaxoSmithKline and consulting and lecture fees from Novartis; Dr. de Man, receiving consulting and lecture fees and grant support from Gilead Sciences, consulting fees and grant support from Bristol-Myers Squibb, consulting fees from Novartis, and lecture fees from UCB; Dr. Lee, receiving consulting and lecture fees and grant support from Gilead Sciences, Bristol-Myers Squibb, and Hoffmann–La Roche, consulting fees from Novartis, and grant support from the Canadian Institutes of Health Research and the Canadian Liver Foundation; Dr. Flisiak, receiving consulting and lecture fees from Bristol-Myers Squibb, consulting fees from Human Genome Sciences, and lecture fees from Hoffmann–La Roche and Schering-Plough; Dr. Kaita, receiving consulting and lecture fees from Gilead Sciences and Novartis and lecture fees from Schering-Plough; Dr. Manns, receiving consulting and lecture fees from Gilead Sciences, Novartis, Bristol-Myers Squibb, and Hoffmann–La Roche and lecture fees from GlaxoSmithKline; Dr. Buggisch, receiving lecture fees from Bristol-Myers Squibb, Novartis, and Gilead Sciences; Dr. Weilert, receiving consulting fees from Bristol-Myers Squibb; Dr. Shiffman, receiving consulting and lecture fees and grant support from Gilead Sciences, lecture fees and grant support from Bristol-Myers Squibb, and grant support from Hoffmann–La Roche; Dr. Trinh, receiving consulting and lecture fees, grant support, and nonprofit support from Bristol-Myers Squibb and Gilead Sciences, holding equity ownership or stock in Gilead Sciences, and receiving grant support from Hoffmann–La Roche and nonprofit support from Novartis; Dr. Washington, receiving consulting fees from Gilead Sciences; and Mr. Sorbel, Mr. Quinn, Ms. Snow-Lampart, and Drs. Anderson, Mondou, and Rousseau, being employees of and holding equity in Gilead Sciences. No other potential conflict of interest relevant to this article was reported.
Drs. Marcellin and Heathcote contributed equally to this article.
Source Information
From Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, University of Paris 7 and INSERM Unité 773, Centre de Recherches Claude Bernard sur les Hepatites Virales, Clichy, France (P.M.); University of Toronto, Toronto (E.J.H.), University of Calgary, Calgary, AB (S.S.L.), and John Buhler Research Centre, University of Manitoba, Winnipeg (K.K.) — all in Canada; Hebron Hospital, Barcelona (M.B.); Middlemore Hospital, Auckland (E.G.), and Waikato Hospital, Hamilton (F.W.) — both in New Zealand; Erasmus University Medical Center, Rotterdam, the Netherlands (R.A.D.); University Hospital Saint Ivan Rilsky, Sofia (Z.K.), University Hospital Sveta Marina, Varna (I.K.), and Medical University, Sofia (K.T.) — all in Bulgaria; Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece (G.G.); Medical University of Bialystok, Bialystok, Poland (R.F.); Medizinische Hochschule, Hannover (M.M.), and Medizinische Universitätsklinik Eppendorf, Hamburg (P.B.) — both in Germany; Haydarpasa Numune Hospital, Istanbul, Turkey (O.O.K.); Virginia Commonwealth University Medical Center, Richmond (M.L.S.); San Jose Gastroenterology, San Jose, CA (H.T.); Vanderbilt University Medical Center, Nashville (M.K.W.); and Gilead Sciences, Durham, NC (J.S., J.A., A.S.-L., E.M., J.Q., F.R.). The investigators who enrolled participants in this trial are listed in the Appendix.
Address reprint requests to Dr. Rousseau at Gilead Sciences, 4611 University Dr., Durham, NC, or at frank.rousseau@gilead.com.
Appendix
In addition to the authors, the following investigators participated in the two studies: Australia — W. Cheng, D. Crawford, P. Desmond, J. George, P. Gow, I. Kronborg, M. Ngu, S. Roberts, J. Sasadeusz, W. Sievert, S. Strasser; Bulgaria — R. Balabanska; Canada — F. Anderson, R. Myers, M. Sherman; Czech Republic — P. Husa, J. Sperl, P. Urbanek, M. Volfova; France — K. Barange, Y. Benhamou, J. Bronowicki, C. Hezode, F. Habersetzer, P. Mathurin, C. Trepo, J. Zarski; Germany — T. Berg, W. Boecher, P. Gerken, T. Heintges, H. Hinrichsen, D. Huppe, S. Kaiser, S. Mauss, B. Moller, G. Teuber, R. Zachoval, S. Zeuzem; Greece — G. Dalekos, S. Hadziyannis, G. Kitis; Italy — P. Andreone, M. Rizzetto; New Zealand — C. Moyes, N. Stace; Poland — M. Beniowski, A. Gladysz, W. Halota, A. Horban, W. Kryczka, T. Mach; Spain — J. Calleja, T. Casanovas, J. Enriquez, M. Prieto; Turkey — U. Akarka, S. Gurel, S. Ozenirler, H. Senturk, N. Tozun; United Kingdom — G. Dusheiko, D. Mutimer, R. Williams; United States — N. Afdahl, M. Bennett, N. Bzowej, S. Chan, A. DiBisceglie, P. Gaglio, N. Gitlin, S. Gordon, K. Hu, I. Jacobson, L. Jeffers, A. Lok, P. Martin, T. Min, T. Nguyen, P. Pockros, N. Ravendhran, R. Rubin, V. Rustgi, M. Tong, H. Tsai, C. Wang, Z. Younossi.
- References
References
1
Lai CL ,Ratziu V ,Yuen MF ,Poynard T . Viral hepatitis B. Lancet 2003;362:2089-2094
CrossRef | Web of Science | Medline2
Perz JF ,Armstrong GL ,Farrington LA ,Hutin YJ ,Bell BP . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538
CrossRef | Web of Science | Medline3
Hepatitis B Fact sheet WHO/204. Geneva: World Health Organization, October 2000.
4
Hadziyannis SJ ,Vassilopoulos D . Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-624
CrossRef | Web of Science | Medline5
Funk ML ,Rosenberg DM ,Lok AS . World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61
CrossRef | Web of Science | Medline6
Hadziyannis SJ ,Papatheodoridis GV . Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-141
CrossRef | Web of Science | Medline7
Feld JJ ,Heathcote EJ . Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:116-129
CrossRef | Web of Science | Medline8
Liaw YF ,Sung JJY ,Chow WC , et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
Full Text | Web of Science | Medline9
Dienstag JL ,Schiff ER ,Wright TL , et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
Full Text | Web of Science | Medline10
Perrillo RP ,Schiff ER ,Davis GL , et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301
Full Text | Web of Science | Medline11
Hoofnagle JH ,Peters M ,Mullen KD , et al. Randomized, controlled trial of recombinant human alfa-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-1325
Web of Science | Medline12
Marcellin P ,Chang TT ,Lim SG , et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
Full Text | Web of Science | Medline13
Lau GK ,Piratvisuth T ,Luo KX , et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695
Full Text | Web of Science | Medline14
Chang TT ,Gish RG ,de Man R , et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010
Full Text | Web of Science | Medline15
Lai CL ,Gane E ,Liaw YF , et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588
Full Text | Web of Science | Medline16
Lok AS ,Lai CL ,Leung N , et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722
CrossRef | Web of Science | Medline17
Hoofnagle JH ,Doo E ,Liang TJ ,Fleischer R ,Lok AS . Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-1075
CrossRef | Web of Science | Medline18
Cherrington JM ,Allen SJW ,Bischofberger N ,Chen MS . Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β, and γ. Antivir Chem Chemother 1995;6:217-221
Web of Science19
Heijtink RA ,Kruining J ,de Wilde GA ,Balzarini J ,de Clercq E ,Schalm SW . Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994;38:2180-2182
Web of Science | Medline20
Brunelle MN ,Jacquard AC ,Pichoud C , et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-1398
CrossRef | Web of Science | Medline21
Delaney WE 4th,
Ray AS ,Yang H , et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471-2477
CrossRef | Web of Science | Medline22
Brunelle MN ,Lucifora J ,Neyts J , et al. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007;51:2240-2243
CrossRef | Web of Science | Medline23
Lada O ,Benhamou Y ,Cahour A ,Katlama C ,Poynard T ,Thibault V . In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004;9:353-363
Web of Science | Medline24
van Bommel F ,Zollner B ,Sarrazin C , et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-325
CrossRef | Web of Science | Medline25
Kuo A ,Dienstag JL ,Chung RT . Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-272
CrossRef | Web of Science | Medline26
Neff GW ,Nery J ,Lau DT , et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004;38:1999-2004
CrossRef | Web of Science | Medline27
van Bommel F ,Wunsche T ,Mauss S , et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425
CrossRef | Web of Science | Medline28
Thio CL ,Sulkowski MS ,Thomas DL . Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis 2005;41:1035-1040
CrossRef | Web of Science | Medline29
Peters MG ,Andersen J ,Lynch P , et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-1116
CrossRef | Web of Science | Medline30
Brunt EM . Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000;31:241-246
CrossRef | Web of Science | Medline31
van der Poorten D ,Prakoso E ,Khoo TL , et al. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol 2007;22:1500-1505
CrossRef | Web of Science | Medline32
Gaia S ,Barbon V ,Smedile A , et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008;48:540-547
CrossRef | Web of Science | Medline33
Viread (tenofovir disoproxil fumarate) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, May 2007 (package insert).
34
Hepsera (adefovir dipivoxil) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, October 2006 (package insert).
35
Lin SM ,Yu ML ,Lee CM , et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52
CrossRef | Web of Science | Medline36
Schiff ER ,Lai CL ,Hadziyannis S , et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1427
Web of Science | Medline37
Yuen MF ,Seto W ,Chow D , et al. Long-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy: 7-year experience. Hepatology 2005;42:583A-583A
Web of Science38
Mommeja-Marin H ,Mondou E ,Blum MR ,Rousseau F . Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-1319
CrossRef | Web of Science | Medline39
Lok AS ,Zoulim F ,Locarnini S , et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-265
CrossRef | Web of Science | Medline40
Alberti A ,Clumeck N ,Collins S , et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-624[Erratum, J Hepatol 2005;43:1098.]
CrossRef | Web of Science | Medline41
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. (Accessed November 10, 2008, at http://AIDSinfo.nih.gov.)
42
Hammer SM ,Saag MS ,Schechter M , et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843
CrossRef | Web of Science | Medline43
Lok AS ,McMahon BJ . Chronic hepatitis B. Hepatology 2007;45:507-539[Erratum, Hepatology 2007;45:1347.]
CrossRef | Web of Science | Medline
- Citing Articles (171)
Citing Articles
1
Maria C Segovia, Wadih Chacra, Stuart C Gordon. (2012) Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opinion on Pharmacotherapy 13:2, 245-254
CrossRef2
Anders Boyd, Pierre-Marie Girard, Karine Lacombe. (2012) Consequences of persistent HBV infection in HIV: the double-edged sword of nucleos(t)ide analogs. Future Virology 7:2, 139-148
CrossRef3
Robert Gish, Ji-Dong Jia, Stephen Locarnini, Fabien Zoulim. (2012) Selection of chronic hepatitis B therapy with high barrier to resistance. The Lancet Infectious Diseases
CrossRef4
Olivier Lada, Anne Gervais, Michel Branger, Gilles Peytavin, Benedicte Roquebert, Gilles Collin, Gil Fraqueiro, Rami Moucari, Gwen Hamet, Michelle Martinot-Peignoux, Sophie Matheron, Patrick Marcellin. (2012) Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver International 32:1, 93-101
CrossRef5
(2012) A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. Journal of Viral Hepatitis 19:1, 9-22
CrossRef6
Fabien Zoulim, Stephen Locarnini. (2012) Management of treatment failure in chronic hepatitis B. Journal of Hepatology 56, S112-S122
CrossRef7
Tsunamasa Watanabe, Fuminaka Sugauchi, Shigeru Kusumoto, Noboru Shinkai, Etsuko Iio, Kentarou Matsuura, Atsunori Kusakabe, Tomokatsu Miyaki, Syunsuke Nojiri, Yasuhito Tanaka. (2012) A case report of successful therapy with tenofovir for a multi-drug resistant chronic hepatitis B patient complicated with malignant lymphoma. Kanzo 53:1, 35-41
CrossRef8
Henry Lik-Yuen Chan, Vincent Wai-Sun Wong. 2012. Hepatitis B. , 540-563.
CrossRef9
Jennifer C. Lai, Norah A. Terrault. 2012. Recurrent Viral Diseases after Liver Transplantation. , 883-909.
CrossRef10
Anna S. F. Lok, Francesco Negro. 2011. Hepatitis B and D. , 537-581.
CrossRef11
Martín Prieto, María García-Eliz. (2011) Management of hepatitis B virus infection in the pre-transplant setting. Digestive and Liver Disease Supplements 5:1, 10-14
CrossRef12
J. Fung, C.-L. Lai, W.-K. Seto, M.-F. Yuen. (2011) Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. Journal of Antimicrobial Chemotherapy 66:12, 2715-2725
CrossRef13
Michael Chang, Sammy Saab. (2011) Interferon for Hepatitis B: Which Populations Benefit the Most. Current Hepatitis Reports 10:4, 285-291
CrossRef14
Helen Dakin, Morris Sherman, Scott Fung, Carrie Fidler, Anthony Bentley. (2011) Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective. PharmacoEconomics 29:12, 1075-1091
CrossRef15
Petros C. Benias, Albert D. Min. (2011) Goals of Antiviral Therapy for Hepatitis B: HBeAg Seroconversion, HBsAg Seroconversion, Histologic Improvement, and Possible Impact on Risk of Hepatocellular Carcinoma. Current Hepatitis Reports 10:4, 292-296
CrossRef16
Yuk-Fai Lam, Man-Fung Yuen, Wai-Kay Seto, Ching-Lung Lai. (2011) Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Current Hepatitis Reports 10:4, 235-243
CrossRef17
Olivier Lada, Tarik Asselah, Patrick Marcellin. (2011) Hepatitis B virus Resistance to Antivirals : Diagnosis and Management. Current Hepatitis Reports 10:4, 244-254
CrossRef18
Stefan Mauss, Florian Berger, Natalie Filmann, Dietrich Hueppe, Julia Henke, Petra Hegener, Christoph Athmann, Guenther Schmutz, Eva Herrmann. (2011) Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. Journal of Hepatology 55:6, 1235-1240
CrossRef19
M. Trapero-Marugán, R. Moreno-Otero. (2011) Tratamiento de las hepatitis virales. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6249-6254
CrossRef20
Seyed-Moayed Alavian. (2011) Dilemma of recurrence of hepatitis B infection after liver transplantation. Liver International 31:10, 1422-1423
CrossRef21
Bettina E. Hansen, Vincent Rijckborst, Martijn J. ter Borg, Harry L.A. Janssen. (2011) HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. Journal of Medical Virology 83:11, 1917-1923
CrossRef22
S. Amini-Bavil-Olyaee, U. Herbers, T. Luedde, C. Trautwein, F. Tacke. (2011) Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains. Journal of Viral Hepatitis 18:11, 804-814
CrossRef23
W. S. Ayoub, E. B. Keeffe. (2011) Review article: current antiviral therapy of chronic hepatitis B. Alimentary Pharmacology & Therapeutics 34:10, 1145-1158
CrossRef24
C. Q. Pan, K.-Q. Hu, A. S. Yu, W. Chen, C. Bunchorntavakul, K. R. Reddy. (2011) Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. Journal of Viral Hepatitisno-no
CrossRef25
Melanie A. Mallory, Sam R. Page, David R. Hillyard. (2011) Development and validation of a hepatitis B virus DNA sequencing assay for assessment of antiviral resistance, viral genotype and surface antigen mutation status. Journal of Virological Methods 177:1, 31-37
CrossRef26
Derek Yu, Jenny Heathcote. (2011) Tenofovir in the treatment of chronic hepatitis B. Therapy 8:5, 527-544
CrossRef27
Mauro Viganò, Pietro Lampertico, Massimo Colombo. (2011) Drug safety evaluation of adefovir in HBV infection. Expert Opinion on Drug Safety 10:5, 809-818
CrossRef28
Chih-Lin Lin, Jia-Horng Kao. (2011) Recent advances in the treatment of chronic hepatitis B. Expert Opinion on Pharmacotherapy 12:13, 2025-2040
CrossRef29
Maximilian Lee, Emmet B. Keeffe. (2011) Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance. Gastroenterology Clinics of North America 40:3, 495-505
CrossRef30
William W. L. Wong, Gloria Woo, E. Jenny Heathcote, Murray Krahn. (2011) Cost effectiveness of screening immigrants for hepatitis B. Liver International 31:8, 1179-1190
CrossRef31
Erik De Clercq. 2011. Discovery and Development of Tenofovir Disoproxil Fumarate. , 85-101.
CrossRef32
Anais Vallet-Pichard, Hélène Fontaine, Vincent Mallet, Stanislas Pol. (2011) VIRAL hepatitis in solid organ transplantation other than liver. Journal of Hepatology 55:2, 474-482
CrossRef33
C. Sarrecchia, V. Svicher, A. Volpi, R. Salpini, L. Ceccarelli, P. Sordillo, A. Bertoli, C. F. Perno, M. Andreoni. (2011) Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. Infection 39:4, 367-370
CrossRef34
R. Moucari, N. Boyer, M.-P. Ripault, C. Castelnau, V. Mackiewicz, A. Dauvergne, D. Valla, M. Vidaud, M.-H. N. Chanoine, P. Marcellin. (2011) Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. Journal of Viral Hepatitis 18:8, 580-586
CrossRef35
Hatef Massoumi, Paul Martin, Hui-Hui Tan. (2011) Management of chronic hepatitis B. European Journal of Gastroenterology & Hepatology 23:8, 642-650
CrossRef36
M. J. Sonneveld, R. Zoutendijk, H. L. A. Janssen. (2011) Hepatitis B surface antigen monitoring and management of chronic hepatitis B. Journal of Viral Hepatitis 18:7, 449-457
CrossRef37
Hongyan Liu, Richeng Mao, Lili Fan, Jiahui Xia, Yiliang Li, Yongxi Yin, Xinyan Li, Xu Zhao, Hongying Guo, Haoxiang Zhu, Yongmei Zhang, Yaoyue Kang, Jiming Zhang. (2011) Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array. Journal of Virological Methods 175:1, 1-6
CrossRef38
W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. J. Fontana, T. Licari, A. S. F. Lok. (2011) Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. Journal of Viral Hepatitisno-no
CrossRef39
Wai-Kay Seto, Man-Fung Yuen, James Fung, Ching-Lung Lai. (2011) Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatology International
CrossRef40
Li-Chun Wang, En-Qiang Chen, Jing Cao, Li Liu, Li Zheng, Da-Jiang Li, Lu Xu, Xue-Zhong Lei, Cong liu, Hong Tang. (2011) De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients. Hepatology International 5:2, 671-676
CrossRef41
Chanunta Hongthanakorn, Watcharasak Chotiyaputta, Kelly Oberhelman, Robert J. Fontana, Jorge A. Marrero, Tracy Licari, Anna S. F. Lok. (2011) Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53:6, 1854-1863
CrossRef42
Joseph K. Lim, Mindie H. Nguyen. (2011) The Role of Hepatic Steatosis in Chronic Hepatitis B Infection. Current Hepatitis Reports 10:2, 134-141
CrossRef43
Nirupma TrehanPati, Shyam Kotillil, Syed S. Hissar, Shikha Shrivastava, Arshi Khanam, Sukriti Sukriti, Siddartha K. Mishra, Shiv Kumar Sarin. (2011) Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate. Journal of Clinical Immunology 31:3, 509-520
CrossRef44
M. H. Eckman, T. E. Kaiser, K. E. Sherman. (2011) The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States. Clinical Infectious Diseases 52:11, 1294-1306
CrossRef45
Jeong-Hoon Lee, Jung-Hwan Yoon, Eun Ju Cho, Hyo Joon Yang, Eun Sun Jang, Min-Sun Kwak, Sang Youn Hwang, Su Jong Yu, Chang-Hoon Lee, Yoon Jun Kim, Chung Yong Kim, Hyo-Suk Lee. (2011) Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Journal of Clinical Gastroenterology1
CrossRef46
Richard L. Mackman, Tomas Cihlar. 2011. Acyclic and Cyclic Nucleoside Phosphonates. , 91-128.
CrossRef47
Hejun Yuan, William M Lee. (2011) Update of chronic hepatitis B. Current Opinion in Gastroenterology 27:3, 217-223
CrossRef48
István Tornai. (2011) Interferonalapú versus direkt antivirális terápia a krónikus B hepatitis kezelésében. Orvosi Hetilap 152:22, 869-874
CrossRef49
Anna S. F. Lok. 2011. Hepatitis B. , 367-392.
CrossRef50
Shuang Wu, Kenichi Fukai, Fumio Imazeki, Makoto Arai, Tatsuo Kanda, Yutaka Yonemitsu, Osamu Yokosuka. (2011) Initial Virological Response and Viral Mutation with Adefovir Dipivoxil Added to Ongoing Lamivudine Therapy in Lamivudine-Resistant Chronic Hepatitis B. Digestive Diseases and Sciences 56:4, 1207-1214
CrossRef51
Giampiero Carosi, Mario Rizzetto, Alfredo Alberti, Giuseppe Cariti, Massimo Colombo, Antonio Craxì, Gaetano Filice, Massimo Levrero, Francesco Mazzotta, Giuseppe Pastore, Felice Piccinino, Daniele Prati, Giovanni Raimondo, Evangelista Sagnelli, Mario Toti, Maurizia Brunetto, Raffaele Bruno, Vito Di Marco, Carlo Ferrari, Giovanni B. Gaeta, Pietro Lampertico, Alfredo Marzano, Teresa Pollicino, Massimo Puoti, Teresa Santantonio, Antonina Smedile. (2011) Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. Digestive and Liver Disease 43:4, 259-265
CrossRef52
Vincenza Calvaruso, Antonio Craxì. (2011) Fibrosis in chronic viral hepatitis. Best Practice & Research Clinical Gastroenterology 25:2, 219-230
CrossRef53
Pin-Nan Cheng, Wen-Chun Liu, Hung-Wen Tsai, I-Chin Wu, Ting-Tsung Chang, Kung-Chia Young. (2011) Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. Journal of Medical Virology 83:4, 602-607
CrossRef54
Hellan Kwon, Anna S. Lok. (2011) Hepatitis B therapy. Nature Reviews Gastroenterology & Hepatology
CrossRef55
Hyo-Suk Lee, Byung Chul Yoo, Kwan Sik Lee, Ju Hyun Kim, Soon-Ho Um, Soo Hyung Ryu, Young-Suk Lee, Young Soo Kim, Kwon Yoo, Joon-Yeol Han, Jae Seok Hwang, Tae-Hun Kim, Jin-Mo Yang, Heon-Ju Lee, Chae Yoon Chon, Mong Cho, Byung Hoon Han, Seong Gyu Hwang, Kwan Soo Byun, Young-Hwa Chung, Se-Hyun Cho, Kwang Cheol Koh, Byung-Ik Kim, Haak Cheoul Kim, Seung Woon Paik, Myung-Seok Lee, Hee-Won Yoo, Cheol Ju Han. (2011) Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy. Journal of Gastroenterology 46:3, 410-414
CrossRef56
Hitendra Garg, Shiv Kumar Sarin, Manoj Kumar, Vishal Garg, Barjesh Chander Sharma, Ashish Kumar. (2011) Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53:3, 774-780
CrossRef57
Steven-Huy Han, K. Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Robert Gish, Raymond T. Chung, Bulent Degertekin, Anna Lok, . (2011) Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clinical Transplantation 25:2, E152-E162
CrossRef58
V. Rijckborst, M. J. Sonneveld, H. L. A. Janssen. (2011) Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?. Alimentary Pharmacology & Therapeutics 33:5, 501-513
CrossRef59
Mauro Viganò, Pietro Lampertico. (2011) Antiviral drugs for HBV liver disease. Expert Opinion on Biological Therapy 11:3, 285-300
CrossRef60
Andrea Snow-Lampart, Brandi Chappell, Maria Curtis, Yuao Zhu, Florence Myrick, James Schawalder, Kathryn Kitrinos, Evguenia S. Svarovskaia, Michael D. Miller, Jeff Sorbel, Jenny Heathcote, Patrick Marcellin, Katyna Borroto-Esoda. (2011) No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53:3, 763-773
CrossRef61
Tatyana A. Shamliyan, James R. Johnson, Roderick MacDonald, Aasma Shaukat, Jian-Min Yuan, Robert L. Kane, Timothy J. Wilt. (2011) Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection. Journal of General Internal Medicine 26:3, 326-339
CrossRef62
Erik De Clercq. (2011) A 40-Year Journey in Search of Selective Antiviral Chemotherapy*. Annual Review of Pharmacology and Toxicology 51:1, 1-24
CrossRef63
Emilio Suárez, Ana Gila, Blanca Figueruela, Natalia Chueca, Pilar Muñoz Rueda, Beatriz Puche, Enrique Fraga, Federico García, Juan Manuel Martín, Raúl J. Andrade, Carmen Nogales, Manuel Romero-Gómez, Javier Salmerón. (2011) La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados. Gastroenterología y Hepatología 34:2, 69-74
CrossRef64
Wedemeyer, Heiner, Yurdaydìn, Cihan, Dalekos, George N., Erhardt, Andreas, Çakaloğlu, Yilmaz, Değertekin, Halil, Gürel, Selim, Zeuzem, Stefan, Zachou, Kalliopi, Bozkaya, Hakan, Koch, Armin, Bock, Thomas, Dienes, Hans Peter, Manns, Michael P., . (2011) Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta. New England Journal of Medicine 364:4, 322-331
Full Text65
Chih-Lin Lin, Jia-Horng Kao. (2011) The clinical implications of hepatitis B virus genotype: Recent advances. Journal of Gastroenterology and Hepatology 26, 123-130
CrossRef66
Usama Elewa, Ana Maria Sandri, W. Ray Kim, Fernando C. Fervenza. (2011) Treatment of Hepatitis B Virus-Associated Nephropathy. Nephron Clinical Practice 119:1, c41-c49
CrossRef67
Carrie R. Wong, Huy N. Trinh, Benjamin Yip, Huy A. Nguyen, Ruel T. Garcia, Aijaz Ahmed, Emmet B. Keeffe, Mindie H. Nguyen. (2011) High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. Journal of Clinical Gastroenterology 45:10, 900-905
CrossRef68
George V. Papatheodoridis. (2011) Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver International 31, 95-103
CrossRef69
Kumaresan Yogeswaran, Scott K. Fung. (2011) Chronic hepatitis B in pregnancy: unique challenges and opportunities. The Korean Journal of Hepatology 17:1, 1
CrossRef70
E. Jenny Heathcote, Patrick Marcellin, Maria Buti, Edward Gane, Robert A. De Man, Zahary Krastev, George Germanidis, Samuel S. Lee, Robert Flisiak, Kelly Kaita, Michael Manns, Iskren Kotzev, Konstantin Tchernev, Peter Buggisch, Frank Weilert, Oya Ovunc Kurdas, Mitchell L. Shiffman, Huy Trinh, Selim Gurel, Andrea Snow–Lampart, Katyna Borroto–Esoda, Elsa Mondou, Jane Anderson, Jeff Sorbel, Franck Rousseau. (2011) Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. Gastroenterology 140:1, 132-143
CrossRef71
Shu-Shan Zhao, Lan-Hua Tang, Xia-Hong Dai, Wei Wang, Rong-Rong Zhou, Li-Zhang Chen, Xue-Gong Fan. (2011) Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review. Virology Journal 8:1, 111
CrossRef72
Soon Sun Kim, Jae Youn Cheong, Sung Won Cho. (2011) Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut and Liver 5:3, 278
CrossRef73
Yun-Fan Liaw, I-Shyan Sheen, Chuan-Mo Lee, Ulus Salih Akarca, George V. Papatheodoridis, Florence Suet-Hing Wong, Ting-Tsung Chang, Andrzej Horban, Chia Wang, Peter Kwan, Maria Buti, Martin Prieto, Thomas Berg, Kathryn Kitrinos, Ken Peschell, Elsa Mondou, David Frederick, Franck Rousseau, Eugene R. Schiff. (2011) Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53:1, 62-72
CrossRef74
Itaru Ozeki, Yoshiyasu Karino, Jun Akaike, Rikuumi Kimura, Tomohiro Arakawa, Tomoaki Nakashima, Yasuaki Kuwata, Takumi Ohmura, Takahiro Sato, Joji Toyota. (2011) Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Kanzo 52:2, 102-111
CrossRef75
Milan J. Sonneveld, Harry L. A. Janssen. (2011) Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?. Liver International 31, 78-84
CrossRef76
Fabien Zoulim. (2011) Hepatitis B virus resistance to antiviral drugs: where are we going?. Liver International 31, 111-116
CrossRef77
Nancy Leung. (2011) Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. Liver International 31, 85-89
CrossRef78
Jia-Horng Kao. (2011) Molecular Epidemiology of Hepatitis B Virus. The Korean Journal of Internal Medicine 26:3, 255
CrossRef79
Wen-cong Li, Mao-rong Wang, Ling-bo Kong, Wei-guang Ren, Yu-guo Zhang, Yue-min Nan. (2011) Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infectious Diseases 11:1, 165
CrossRef80
Yun-Fan Liaw. (2011) Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver International 31, 117-121
CrossRef81
Theodora E.M.S. de Vries–Sluijs, Jurriën G.P. Reijnders, Bettina E. Hansen, Hans L. Zaaijer, Jan M. Prins, Suzan D. Pas, Martin Schutten, Andy I.M. Hoepelman, Clemens Richter, Jan W. Mulder, Rob A. de Man, Harry L.A. Janssen, Marchina E. van der Ende. (2010) Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. Gastroenterology 139:6, 1934-1941
CrossRef82
Roos E. Barth, Quirine Huijgen, Jantjie Taljaard, Andy I.M. Hoepelman. (2010) Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. International Journal of Infectious Diseases 14:12, e1024-e1031
CrossRef83
Helen Dakin, Anthony Bentley, Geoff Dusheiko. (2010) Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B. Value in Health 13:8, 922-933
CrossRef84
Helen Dakin, Carrie Fidler, Christie Harper. (2010) Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis B. Value in Health 13:8, 934-945
CrossRef85
Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2010) HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver International 30:10, 1461-1470
CrossRef86
Robert S. Brown. (2010) Thrombocytopenia With Abnormal Liver Function Tests. Clinical Gastroenterology and Hepatology 8:11, 920-923
CrossRef87
Tsung-Jung Liang, King-Tong Mok, Shiuh-Inn Liu, Shiu-Feng Huang, Nan-Hua Chou, Cheng-Chung Tsai, I.-Shu Chen, Ming-Hsin Yeh, Yu-Chia Chen, Being-Whey Wang. (2010) Hepatitis B Genotype C Correlated with Poor Surgical Outcomes for Hepatocellular Carcinoma. Journal of the American College of Surgeons 211:5, 580-586
CrossRef88
Alice M Jenh, Paul A Pham. (2010) Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Review of Anti-infective Therapy 8:10, 1079-1092
CrossRef89
Perumal Vivekanandan, Om Vir Singh. (2010) Molecular methods in the diagnosis and management of chronic hepatitis B. Expert Review of Molecular Diagnostics 10:7, 921-935
CrossRef90
Yun-Fan Liaw, George K. K. Lau, Jia-Horng Kao, Edward Gane. (2010) Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection. Digestive Diseases and Sciences 55:10, 2727-2734
CrossRef91
Thomas Berg, Patrick Marcellin, Fabien Zoulim, Bernd Moller, Huy Trinh, Sing Chan, Emilio Suarez, Fabien Lavocat, Andrea Snow–Lampart, David Frederick, Jeff Sorbel, Katyna Borroto–Esoda, David Oldach, Franck Rousseau. (2010) Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. Gastroenterology 139:4, 1207-1217.e3
CrossRef92
W. Chotiyaputta, A. S. F. Lok. (2010) Endpoints of hepatitis B treatment. Journal of Viral Hepatitis 17:10, 675-684
CrossRef93
Gloria Woo, George Tomlinson, Yasunori Nishikawa, Matthew Kowgier, Morris Sherman, David K.H. Wong, Ba Pham, Wendy J. Ungar, Thomas R. Einarson, E. Jenny Heathcote, Murray Krahn. (2010) Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses. Gastroenterology 139:4, 1218-1229.e5
CrossRef94
W. Ray Kim, John J. Poterucha. 2010. Hepatitis B and C. , 186-199.
CrossRef95
Erik De Clercq. 2010. HIV Reverse Transcriptase Inhibitors. .
CrossRef96
Piero Luigi Almasio, Calogero Cammà, Vito Di Marco, Antonio Craxì. 2010. Hepatitis B: Prognosis and Treatment. , 448-464.
CrossRef97
Rami Moucari. (2010) Peginterferon for chronic hepatitis B: Predicting success with on-treatment benchmarks. Journal of Gastroenterology and Hepatology 25:9, 1474-1475
CrossRef98
Chanunta Hongthanakorn, Anna S.F. Lok. (2010) New Pharmacologic Therapies in Chronic Hepatitis B. Gastroenterology Clinics of North America 39:3, 659-680
CrossRef99
Lynne Strasfeld, Sunwen Chou. (2010) Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infectious Disease Clinics of North America 24:3, 809-833
CrossRef100
Hie-Won L. Hann, Stephen R. Dunn, Meejin Ahn, So Young Park. (2010) Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009). Journal of Medical Virology 82:9, 1489-1493
CrossRef101
Tatsuya Ide, Michio Sata, Kazuaki Chayama, Michiko Shindo, Joji Toyota, Satoshi Mochida, Eiichi Tomita, Hiromitsu Kumada, Gotaro Yamada, Hiroshi Yatsuhashi, Norio Hayashi, Hiroki Ishikawa, Taku Seriu, Masao Omata. (2010) Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatology International 4:3, 594-600
CrossRef102
Hui-Hui Tan, Paul Martin. (2010) Management of End-Stage Liver Disease in Chronic Hepatitis B. Clinics in Liver Disease 14:3, 477-493
CrossRef103
Vincent Rijckborst, Martijn J ter Borg, Yilmaz Cakaloglu, Peter Ferenci, Fehmi Tabak, Meral Akdogan, Krzysztof Simon, Maria Raptopoulou-Gigi, Necati Örmeci, Pieter E Zondervan, Elke Verhey, Anneke J van Vuuren, Bettina E Hansen, Harry LA Janssen. (2010) A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. The American Journal of Gastroenterology 105:8, 1762-1769
CrossRef104
Vincent Rijckborst, Bettina E. Hansen, Yilmaz Cakaloglu, Peter Ferenci, Fehmi Tabak, Meral Akdogan, Krzysztof Simon, Ulus S. Akarca, Robert Flisiak, Elke Verhey, Anneke J. Van Vuuren, Charles A. B. Boucher, Martijn J. ter Borg, Harry L. A. Janssen. (2010) Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52:2, 454-461
CrossRef105
María L. Cuestas, Verónica L. Mathet, José R. Oubiña, Alejandro Sosnik. (2010) Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection. Pharmaceutical Research 27:7, 1184-1202
CrossRef106
Erik De Clercq. (2010) Antiviral therapy: quo vadis ?. Future Medicinal Chemistry 2:7, 1049-1053
CrossRef107
Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Kenneth Kar-Lung Yan, Angel Mei-Ling Chim, Hoi-Yun Chan, Chi-Hang Tse, Paul Cheung-Lung Choi, Anthony Wing-Hung Chan, Joseph Jao-Yiu Sung, Henry Lik-Yuen Chan. (2010) Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:6, 1945-1953
CrossRef108
Lynne Strasfeld, Sunwen Chou. (2010) Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infectious Disease Clinics of North America 24:2, 413-437
CrossRef109
Vandana Khungar, Steven-Huy Han. (2010) A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Current Hepatitis Reports 9:2, 75-90
CrossRef110
Rong-Nan Chien. (2010) On-treatment monitoring of chronic hepatitis B virus infection: An Asian-Pacific perspective. Journal of Gastroenterology and Hepatology 25:5, 852-857
CrossRef111
Milan J. Sonneveld, Harry L. A. Janssen. (2010) Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Current Hepatitis Reports 9:2, 91-98
CrossRef112
R. B. Takkenberg, C. J. Weegink, H. L. Zaaijer, H. W. Reesink. (2010) New developments in antiviral therapy for chronic hepatitis B. Vox Sanguinis 98:4, 481-494
CrossRef113
Markus Peck-Radosavljevic, Johann Deutsch, Peter Ferenci, Ivo Graziadei, Harald Hofer, Heidemarie Holzmann, Wolf-Dietrich Huber, Herman Laferl, Andreas Maieron, Rudolf Stauber, Wolfgang Vogel. (2010) 4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009. Wiener klinische Wochenschrift 122:9-10, 280-302
CrossRef114
Jonathan G. Stine, Omar S. Khokhar, John Charalambopoulos, Victoria K. Shanmugam, James H. Lewis. (2010) Rheumatologists' awareness of and screening practices for Hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care & Research 62:5, 704-711
CrossRef115
James J. Kohler, William Lewis. 2010. Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy. , 313-332.
CrossRef116
Xavier Verhelst, Hans Orlent, Isabelle Colle, Anja Geerts, Martine De Vos, Hans Van Vlierberghe. (2010) Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. European Journal of Gastroenterology & Hepatology 22:4, 494-499
CrossRef117
Man-Fung Yuen, Kwang-Hyub Han, Soon-Ho Um, Seung Kew Yoon, Hye-Ryon Kim, John Kim, Chung Ryeol Kim, Ching-Lung Lai. (2010) Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 51:3, 767-776
CrossRef118
Young Kul Jung, Ji Hoon Kim, Young Sun Lee, Hyun Jung Lee, Eileen Yoon, Eun Suk Jung, Seung Kwon Hong, Moon Kyung Joo, Jong Eun Yeon, Jong Jae Park, Jae Seon Kim, Young-Tae Bak, Kwan Soo Byun. (2010) Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naïve, Hepatitis B e Antigen-positive Patients Receiving Entecavir. Journal of Clinical Gastroenterology1
CrossRef119
J. Sun, J. L. Hou. (2010) Management of chronic hepatitis B: experience from China. Journal of Viral Hepatitis 17, 10-17
CrossRef120
L.-C. Wang, E.-Q. Chen, J. Cao, L. Liu, J.-R. Wang, B.-J. Lei, H. Tang. (2010) Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. Journal of Viral Hepatitis 17:3, 178-184
CrossRef121
Sara Raimondi, Patrick Maisonneuve, Savino Bruno, Mario U. Mondelli. (2010) Is response to antiviral treatment influenced by hepatitis B virus genotype?. Journal of Hepatology 52:3, 441-449
CrossRef122
, Sang Hoon Ahn, Henry L. Y. Chan, Pei-Jer Chen, Jun Cheng, Mahesh K. Goenka, Jinlin Hou, Seng Gee Lim, Masao Omata, Teerha Piratvisuth, Qing Xie, Hyung Joon Yim, Man-Fung Yuen. (2010) Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatology International 4:1, 386-395
CrossRef123
L. Martin-Carbonero, V. Soriano. (2010) New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Journal of Antimicrobial Chemotherapy 65:3, 379-382
CrossRef124
Robert J. Fontana. (2010) Entecavir in decompensated HBV cirrhosis: The future is looking brighter. Journal of Hepatology 52:2, 147-149
CrossRef125
A. Tamori, M. Enomoto, S. Kobayashi, S. Iwai, H. Morikawa, H. Sakaguchi, D. Habu, S. Shiomi, Y. Imanishi, N. Kawada. (2010) Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. Journal of Viral Hepatitis 17:2, 123-129
CrossRef126
Ting-Tsung Chang, Ching-Lung Lai, Seung Kew Yoon, Samuel S. Lee, Henrique Sergio M. Coelho, Flair Jose Carrilho, Fred Poordad, Waldemar Halota, Yves Horsmans, Naoky Tsai, Hui Zhang, Daniel J. Tenney, Ricardo Tamez, Uchenna Iloeje. (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:2, 422-430
CrossRef127
Si Nafa Si Ahmed, Marie Ecochard, Fabien Zoulim. (2010) End points of therapy in chronic hepatitis B. Expert Review of Gastroenterology & Hepatology 4:1, 37-49
CrossRef128
R. Sombié, A. Bougouma, O. Diallo, G. Bonkoungou, R. Cissé, L. Sangare, R. Sia, K. Serme, D. Ilboudo. (2010) Hépatite B chronique: aspects épidémiologique, diagnostique, thérapeutique et évolutif au centre hospitalier universitaire Yalgado Ouédraogo de Ouagadougou. Journal Africain d'Hépato-Gastroentérologie 4:1, 3-10
CrossRef129
Moon Seok Choi, Byung Chul Yoo. (2010) Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines. Gut and Liver 4:1, 15
CrossRef130
Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Katja Deterding, Jörg Petersen, Peter Buggisch, Andreas Erhardt, Dietrich Hüppe, Kerstin Stein, Jörg Trojan, Christoph Sarrazin, Wulf O. Böcher, Ulrich Spengler, Hermann E. Wasmuth, Jurrien G.P. Reinders, Bernd Möller, Peter Rhode, Heinz-Hubert Feucht, Bertram Wiedenmann, Thomas Berg. (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:1, 73-80
CrossRef131
Ting-Tsung Chang. (2009) On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatology International 3:S1, 16-23
CrossRef132
C.P. Strassburg, M. Cornberg. (2009) Diagnostik und Therapie der Hepatitis. Der Internist 50:12, 1358-1368
CrossRef133
Tin Nguyen, Paul Desmond, Stephen Locarnini. (2009) The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatology International 3:S1, 5-15
CrossRef134
Giselle Holness, Damaris C Carriero, Douglas T Dieterich. (2009) Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 3:6, 693-699
CrossRef135
Fabien Zoulim, Stephen Locarnini. (2009) Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. Gastroenterology 137:5, 1593-1608.e2
CrossRef136
(2009) Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation 9, S1-S155
CrossRef137
W. Ray Kim, Norah A. Terrault, Rachel A. Pedersen, Terry M. Therneau, Erick Edwards, Andrew A. Hindman, Carol L. Brosgart. (2009) Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States. Gastroenterology 137:5, 1680-1686
CrossRef138
Caroline M. Perry, Dene Simpson. (2009) Tenofovir Disoproxil Fumarate. Drugs 69:16, 2245-2256
CrossRef139
Christian Markus Lange, Bernd Kronenberger, Stefan Zeuzem. (2009) Hepatitis B: Management of suboptimal response to oral antiviral therapy. Current Hepatitis Reports 8:4, 173-180
CrossRef140
Hui-Hui Tan, Paul Martin. (2009) Current treatment of chronic HBV infection: A North American perspective. Current Hepatitis Reports 8:4, 148-153
CrossRef141
Geoffrey Dusheiko, Tabinda Burney. (2009) Current treatment of chronic HBV infection: A European perspective. Current Hepatitis Reports 8:4, 141-147
CrossRef142
Maria Buti, Max Brosa, Miguel A. Casado, Magdalena Rueda, Rafael Esteban. (2009) Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Journal of Hepatology 51:4, 640-646
CrossRef143
Alice M Jenh, Chloe L Thio, Paul A Pham. (2009) Tenofovir for the Treatment of Hepatitis B Virus. Pharmacotherapy 29:10, 1212-1227
CrossRef144
Erik De Clercq. (2009) The history of antiretrovirals: key discoveries over the past 25 years. Reviews in Medical Virology 19:5, 287-299
CrossRef145
Anna S. F. Lok, Brian J. McMahon. (2009) Chronic hepatitis B: Update 2009. Hepatology 50:3, 661-662
CrossRef146
Yun-Fan Liaw. (2009) HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatology International 3:3, 425-433
CrossRef147
Paul D. Griffiths. (2009) A perspective on antiviral resistance. Journal of Clinical Virology 46:1, 3-8
CrossRef148
Stevan A Gonzalez, Emmet B Keeffe. (2009) Chronic hepatitis B and C: update on therapy. Future Virology 4:5, 437-452
CrossRef149
Ching-Lung Lai, Man-Fung Yuen. (2009) The saga of entecavir. Hepatology International 3:3, 421-424
CrossRef150
Rami Moucari, Olivier Lada, Patrick Marcellin. (2009) Chronic hepatitis B: back to the future with HBsAg. Expert Review of Anti-infective Therapy 7:6, 633-636
CrossRef151
V. W.-S. Wong, J. J.-Y. Sung. (2009) Antiviral therapy for chronic hepatitis B: are we doing any good to patients?. Journal of Antimicrobial Chemotherapy 64:2, 223-226
CrossRef152
Watcharasak Chotiyaputta, Anna S. F. Lok. (2009) Hepatitis B virus variants. Nature Reviews Gastroenterology & Hepatology 6:8, 453-462
CrossRef153
Erik De Clercq. (2009) Antiviral chemotherapy in 2009: quo vadis?. Future Virology 4:4, 313-315
CrossRef154
Erik De Clercq. (2009) Another ten stories in antiviral drug discovery (part C): “Old” and “new” antivirals, strategies, and perspectives. Medicinal Research Reviews 29:4, 611-645
CrossRef155
Vincent Wai-Sun Wong, Henry Lik-Yuen Chan. (2009) Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. Journal of Gastroenterology and Hepatology 24:7, 1179-1186
CrossRef156
Anais Vallet-Pichard, Vincent Mallet, Charlotte E Costentin, Stanislas Pol. (2009) Treatment of HBV-related cirrhosis. Expert Review of Anti-infective Therapy 7:5, 527-535
CrossRef157
Patrick Marcellin, Ferruccio Bonino, George K.K. Lau, Patrizia Farci, Cihan Yurdaydin, Teerha Piratvisuth, Rui Jin, Selim Gurel, Zhi-Meng Lu, Jian Wu, Matei Popescu, Stephanos Hadziyannis. (2009) Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a. Gastroenterology 136:7, 2169-2179.e4
CrossRef158
Marc G. Ghany, Edward C. Doo. (2009) Antiviral resistance and hepatitis B therapy. Hepatology 49:S5, S174-S184
CrossRef159
Jules L. Dienstag. (2009) Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 49:S5, S112-S121
CrossRef160
Man-Fung Yuen, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai. (2009) Prevention and management of drug resistance for antihepatitis B treatment. The Lancet Infectious Diseases 9:4, 256-264
CrossRef161
Vito Di Marco, Antonio Craxì. (2009) Chronic hepatitis B: who to treat and which choice of treatment?. Expert Review of Anti-infective Therapy 7:3, 281-291
CrossRef162
Pietro Lampertico. (2009) Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. Journal of Hepatology 50:4, 644-647
CrossRef163
Susanne Abbrederis, Wolfgang Vogel. (2009) Hepatitis B. Wiener klinische Wochenschrift Education 4:1, 43-55
CrossRef164
(2009) Journal Club. Kidney International 75:5, 453-454
CrossRef165
M. H. Nguyen, E. B. Keeffe. (2009) Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. Journal of Viral Hepatitis 16:3, 149-155
CrossRef166
Amethyst C Kurbegov, Ronald J Sokol. (2009) Hepatitis B therapy in children. Expert Review of Gastroenterology & Hepatology 3:1, 39-49
CrossRef167
Kathryn Nash. (2009) Telbivudine in the treatment of chronic hepatitis B. Advances in Therapy 26:2, 155-169
CrossRef168
Jacyntha A. Sterling. (2009) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 44:2, 193-199
CrossRef169
Ji Hoon Kim. (2009) Clinical outcomes and development of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients. The Korean Journal of Hepatology 15:3, 383
CrossRef170
Min Hwan Kim, Kyung-Ah Kim, June Sung Lee, Hyun Woong Lee, Hyung Joon Kim, Sang Gu Yun, Nam-Hoon Kim, Won Ki Bae, Young Soo Moon. (2009) Efficacy of 48-week clevudine therapy for chronic hepatitis B. The Korean Journal of Hepatology 15:3, 331
CrossRef171
Lai, Ching-Lung, Yuen, Man-Fung, . (2008) Chronic Hepatitis B — New Goals, New Treatment. New England Journal of Medicine 359:23, 2488-2491
Full Text
